Grindeks Sets Out Plans For International Expansion
Follows Record-Breaking Growth For Latvian Firm In 2021
Latvia’s Grindeks has set out plans to expand internationally, including by opening new subsidiaries in the US, Switzerland and EU, following a year of growth for the company.
You may also be interested in...
Celltrion And Rani Partner For Oral Adalimumab
Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.
MGC And GlycoNex Kick Off Denosumab Trial In Japan
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.
Neuraxpharm Brings In Greek Olanzapine Brand
CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.